Beam Therapeutics Inc. (BMV:BEAM)

Market Cap	46.27B +8.1%
Revenue (ttm)	1.02B -84.1%
Net Income	-7.61B
EPS	-81.06
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50
Average Volume	179
Open	604.00
Previous Close	485.00
Day's Range	604.00 - 604.00
52-Week Range	309.00 - 604.00
Beta	n/a
RSI	69.78
Earnings Date	Feb 25, 2026

About Beam Therapeutics

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sic...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 510
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BEAM

Financial Performance

In 2024, Beam Therapeutics's revenue was $63.52 million, a decrease of -83.18% compared to the previous year's $377.71 million. Losses were -$376.74 million, 184.3% more than in 2023.

Financial numbers in USD